CoChat

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK

Martinelli, Erika, Morgillo, Floriana, Troiani, Teresa, Ciardiello, Fortunato · 2017 · Cancer Treatment Reviews
Cited by 146

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ctrv.2016.12.001

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 52

  1. McCubrey, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim Biophys Acta, 1773, 1263, 10.1016/j.bbamcr.2006.10.001 · DOI · Paper page
  2. Cowley, 1994, Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3cells, Cell, 77, 841, 10.1016/0092-8674(94)90133-3 · DOI · Paper page
  3. Sebolt-Leopold, 2004, MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors, Curr Pharm Des, 10, 1907, 10.2174/1381612043384439 · DOI
  4. Friday, 2008, Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy, Clin Cancer Res, 14, 342, 10.1158/1078-0432.CCR-07-4790 · DOI · Paper page
  5. Montagut, 2009, Targeting the RAF–MEK–ERK pathway in cancer therapy, Cancer Lett, 283, 125, 10.1016/j.canlet.2009.01.022 · DOI · Paper page
  6. Neuzillet, 2013, Targeting the Ras–ERK pathway in pancreatic adenocarcinoma, Cancer Metastasis Rev, 32, 147, 10.1007/s10555-012-9396-2 · DOI
  7. Bernards, 2004, GAP control: regulating the regulators of small GTPases, Trends Cell Biol, 14, 377, 10.1016/j.tcb.2004.05.003 · DOI · Paper page
  8. Fischmann, 2009, Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors, Biochemistry, 48, 2661, 10.1021/bi801898e · DOI · Paper page
  9. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  10. Marks, 2008, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signalling pathway genes in lung adenocarcinoma, Cancer Res, 68, 5524, 10.1158/0008-5472.CAN-08-0099 · DOI · Paper page
  11. Murugan, 2009, MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas, Cell Cycle, 8, 2122, 10.4161/cc.8.13.8710 · DOI · Paper page
  12. Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
  13. Zhao, 2014, The clinical development of MEK inhibitors, Nat Rev Clin Oncol, 83, 1
  14. Downward, 1994, The GRB2/Sem-5 adaptor protein, FEBS Lett, 338, 113, 10.1016/0014-5793(94)80346-3 · DOI · Paper page
  15. Avraham, 2000, RAFTK/Pyk2-mediated cellular signaling, Cell Signal, 12, 123, 10.1016/S0898-6568(99)00076-5 · DOI · Paper page
  16. Sondermann, 2004, Structural analysis of autoinhibition in the Ras activator Son of sevenless, Cell, 119, 393, 10.1016/j.cell.2004.10.005 · DOI · Paper page
  17. Margarit, 2003, Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS, Cell, 112, 685, 10.1016/S0092-8674(03)00149-1 · DOI · Paper page
  18. Mitin, 2005, Signaling interplay in Ras superfamily function, Curr Biol, 15, R563, 10.1016/j.cub.2005.07.010 · DOI · Paper page
  19. Ledwith, 1990, Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene, Mol Cell Biol, 10, 1545, 10.1128/MCB.10.4.1545 · DOI
  20. Haystead, 1992, Ordered phosphorylation of p42 mapk by MAP kinase kinase, FEBS Lett, 306, 17, 10.1016/0014-5793(92)80828-5 · DOI · Paper page
  21. Marks, 2008, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma, Cancer Res, 68, 5524, 10.1158/0008-5472.CAN-08-0099 · DOI · Paper page
  22. Janku, 2010, Targeted therapy in non-small-cell lung cancer is it becoming a reality?, Nat Rev Clin Oncol, 7, 401, 10.1038/nrclinonc.2010.64 · DOI · Paper page
  23. Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 497, 10.1126/science.1099314 · DOI · Paper page
  24. Thomas, 2005, Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors, Cold Spring Harb Symp Quant Biol, 70, 73, 10.1101/sqb.2005.70.056 · DOI · Paper page
  25. Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017 · DOI · Paper page
  26. Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454 · DOI · Paper page
  27. Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 · DOI · Paper page
  28. Paik, 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations, J Clin Oncol, 29, 2046, 10.1200/JCO.2010.33.1280 · DOI · Paper page
  29. Sen, 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib, Sci Transl Med, 4, 10.1126/scitranslmed.3003513 · DOI · Paper page
  30. Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
  31. Martinelli, 2010, Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells, Clin Cancer Res, 16, 10.1158/1078-0432.CCR-10-0923 · DOI · Paper page
  32. Morgillo, 2011, Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors, PLoS One, 6, e28841, 10.1371/journal.pone.0028841 · DOI
  33. Zhang, 2010, Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells, Carcinogenesis, 31, 577, 10.1093/carcin/bgq020 · DOI · Paper page
  34. Ji-Young, 2013, Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction, Invest New Drugs, 31
  35. Hainsworth, 2010, A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens, J Thorac Oncol, 5, 1630, 10.1097/JTO.0b013e3181e8b3a3 · DOI · Paper page
  36. Yoon, 2010, KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach, Mol Carcinog, 49, 353, 10.1002/mc.20607 · DOI · Paper page
  37. Troiani, 2012, Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells, Br J Cancer, 106, 1648, 10.1038/bjc.2012.129 · DOI · Paper page
  38. Little, 2012, Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling, Biochem Soc Trans, 40, 73, 10.1042/BST20110647 · DOI
  39. Jänne PA, van den Heuvel M, Barlesi M, Cobo M, Mazieres J, Crinò L et al. Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1. In: LBA45 ESMO meeting; 2016. · DOI
  40. Thiery, 2003, Epithelial-mesenchymal transitions in development and pathologies, Curr Opin Cell Biol, 6, 740, 10.1016/j.ceb.2003.10.006 · DOI · Paper page
  41. Morgillo, 2011, Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors, Br J Cancer, 105, 382, 10.1038/bjc.2011.244 · DOI · Paper page
  42. Buonato, 2014, ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition, Cancer Res, 74, 309, 10.1158/0008-5472.CAN-12-4721 · DOI · Paper page
  43. Eberlein, 2015, Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models, Cancer Res, 75, 2489, 10.1158/0008-5472.CAN-14-3167 · DOI · Paper page
  44. Tricker, 2015, Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer, Cancer Discov, 5, 960, 10.1158/2159-8290.CD-15-0063 · DOI · Paper page
  45. Ciardiello, 2008, EGFR antagonists in cancer treatment, N Engl J Med, 358, 1160, 10.1056/NEJMra0707704 · DOI · Paper page
  46. Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 · DOI · Paper page
  47. Bardelli, 2010, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J Clin Oncol, 8, 1254, 10.1200/JCO.2009.24.6116 · DOI · Paper page
  48. Schwartzberg, 2014, J Clin Oncol, 32, 2240, 10.1200/JCO.2013.53.2473 · DOI · Paper page
  49. De Roock, 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, Lancet Oncol, 12, 594, 10.1016/S1470-2045(10)70209-6 · DOI · Paper page
  50. Troiani, 2013, Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance, Expert Opin Biol Ther, 13, 241, 10.1517/14712598.2012.756469 · DOI
  51. Little, 2011, Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells, Sci Signal, 4, 10.1126/scisignal.2001752 · DOI · Paper page
  52. Atreya, 2015, Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC), J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.103 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F.
Venue
Cancer Treatment Reviews
Publisher
Elsevier BV
Published
2017-02
Volume
53
Pages
61-69
ISSN
0305-7372
Cited by
146
References
30
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (14800)
  • MFAG (17778)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.